Document is current
Any future updates will be listed below
-
Authors
Davila, Marco L.
Brentjens, Renier J. https://orcid.org/0000-0002-3364-5388
- License Information
-
More Information
Article History
First Online: 20 December 2022
Competing interests
: M.L.D. has equity or options to purchase equity in Bellicum, Precision Biosciences and Adicet. M.L.D. has received licensing revenue from CRISPR and Atara Biotherapeutics. M.L.D. has received fees from Adicet, Syncopation, Synthekine and Bellicum. R.J.B. has licensed intellectual property to and collect royalties from Bristol Myers Squibb (BMS), Caribou and Sanofi. R.J.B. received research funding from BMS. R.J.B. is a consultant to BMS, Atara Biotherapeutics, Coimmune and Triumvira, and was a consultant for Gracell Biotechnologies, but ended employment in the past 24 months. R.J.B. is a member of the scientific advisory board for CoImmune and Triumvira.
